At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Gefitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2
In Brief
A Phase 2 clinical trial evaluating Gefitinib, Gemcitabine, and 1 other intervention for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
First PostedDec 2005
Study CompletionJun 2008
TodayJul 2026
First PostedDec 13, 2005
Enrollment StartOct 1, 2004
Study CompletionJun 1, 2008
TodayJul 2, 2026
Posted 20.6 years ago
Interventions
Gefitinibdrug
oral tablet
Gemcitabinedrug
intravenous injection
Carboplatindrug
intravenous injection